Neurology Flashcards
(165 cards)
Mild Cognitive Impairment
Mild cognitive impairment (MCI) is an intermediate state between normal cognition and dementia.
- 10-15%/y conversion to dementia; with smaller temporal lobe volume (MRI), apoE4 allele
- No evidence that therapy delays progression or how to diagnose it
Dementia
Diagnosis?
The American Academy of Neurology has published guidelines for tests that should be performed when making a diagnosis of dementia.
- NC CT or MRI
- NO genetic testing (tau mutations, beta-amyloid, APOE E4 allele)
- CSF ONLY when suspecing CJD - testing for the 14-3-3 protein
- B/W: B12, thyroid
- Depression screen
- Screening tests: MMSE, clock drawing, mini-cog, MOCA (canadian)
Primary Dementia Syndromes
and they are?
Think APPLE
- AD (60%): slow, insidious, little findings other than disorientation, visuospatial probs, depression
- Parkinson/plus: see Parkinson’s
- Pick’s (FTD): pick cells, apathetic, disinhibited, more prominent cog. deficit at presentation
- Lewy body disease: neuronal inclusions, less early mem probs, v hallucinations, parkinsonian
- Endothelial (Vascular): AKA Binswanger’s - no specific treatment other than stroke prevention
- ?Huntington’s
Severity of Dementia (MMSE)
Dementia
Secondary Causes?
Important b/c potentially reversible
- Mimics: 3 D’s (depression, delirium, developement d/o)
- Drugs: EtOH, antihistamine/diarrheal/depressant/epileptic
- Infections/Infarct/inflammation: HIV, syphilis, whipple’s, CJD, vasculitis, MS
- Metabolic: B12, thyroid, vit E, cortisol, electrolytes, liver dz
- Structural: bleed, tumors, CSF (NPH)
Huntington’s Disease
Defn: Sx: Findings: Mgmt: Note:
Normal Pressure Hydrocephalus / NPH
What is it?
Hydrocephalus is either communicating or not communicating type.
DIG: Dementia, Incontinence, Gate disturbance.
Imaging: large ventricles with shallow cerebral sulci
Treatment: repeat or large volume lumbar punctures, VP shunts, SA drains.
Selection for shunt surgery requires positive response to supplementary tests such as large volume LP, extended CSF divergent by a lumbar spinal catheter, or CSF outflow resistance tests
Frontal Lobe Dementia
Defn: Sx: Findings: Mgmt: Note:
Treatment of Dementia (pharmacologic)
We suggest a treatment trial with a cholinesterase inhibitor for patients with mild to moderate dementia (MMSE 10-26). The choice between donepezil, rivastigmine, and galantamine
In patients with moderate to advanced dementia (MMSE memantine (10 mg twice daily) to a cholinesterase inhibitor, or using memantine alone in patients who do not tolerate or benefit from a cholinesterase inhibitor
In patients with severe dementia (MMSE memantine even in severe dementia, given the possibility that memantine may be disease-modifying.
Alzheimer’s Dementia
Diagnosis & prognosis
The form of cerebral amyloidosis from an accumulation of amyloid beta – protein. Incurable.
In AD, memory impairment, specifically loss of memory of recent events, is an essential feature of AD and is usually its first manifestation. Language function and visuospatial skills tend to be affected relatively early, while deficits in executive function and behavioral symptoms often manifest later in the disease course.
Diagnosis:
- Prominent Memory Impairment: newly acquired information (early) and remote events (late)
- And one or more of:
- Aphasia: language disturbance
- Apraxia: inability to carry out skilled motor activities despite intact motor function
- Agnosia: failure to recognize/identify entities despite intact sensory function
- Executive dysfunction: planning, organizing, sequencing, abstracting
- Psychiatric manifestations (BPSD) - Major depression (5-8%), Psychosis (20%)
- Motor manifestations (late) – Parkinsonism (30% late in the course)
- Gradation of Severity:
- Mild MMSE 20-26 - mild functional dependence (ie. finances)
- Moderate MMSE 10-20 - increased dependency (drive, shop, hygiene) and memory impairment
- Severe MMSE <10 - state of total dependence and need for constant supervision
- Treatment:
- Disease modifying
- Cholinesterase inhibitors: donepezil (Aricept), rivastigmine (Exelon), galantamine (Reminyl)
- Mild-moderate AD - shown to improve cognitive function and some behavioural Sx
- Vitamin E (1000 IU bid) and Selegine (5 mg bid)
- Moderate AD - Delays progression by 230 and 215 days respectively
- NMDA Receptor Blockers (Memantine 20 mg daily)
- Moderate-Severe AD - shown to improve global function and cognition
- Other: Ginko Biloba (mild effect but many drug interactions), tacrine (hepatotoxic)
- Cholinesterase inhibitors: donepezil (Aricept), rivastigmine (Exelon), galantamine (Reminyl)
- Behavioural management
- Low dose neuroleptic (Seroquel); trazodone for sleep disturbance
- Symptom relief and support (family/caregiver relief)
-
Prognosis:
- Progressive decline leading to death (average survival is 10 years)
Alzheimer’s Dementia
Treatment
There are no treatments either to stop the progression or reverse the disease.
Mild to moderate (MMSE 10-26): any centrally acting anticholinesterase
- donepezil, rivastigmine, and galantamine
- NSAIDs, ginko, ERT and vitamin E have some benefit
Moderate to advanced dementia (MMSE<10):
- N-methyl-D-aspartate (NMDA) receptor antagonist memantine (10 mg twice daily) to a cholinesterase inhibitor, or using memantine alone in patients who do not tolerate or benefit from a cholinesterase inhibitor
A 28-week randomized trial in 252 patients with Mini Mental Status Examination (MMSE) scores of 3 to 14 (mean approximately 8) at study entry found that memantine significantly reduced deterioration on multiple scales of clinical efficacy
Diffuse Lewy Body Disease
Lewy body dementia = Dementia + Parkinsonism + visual hallucinations + dysautonomia + sleep disorders + neuroleptic sensitivity.
Clinical features:
Central Feature (essential for Dx)
Dementia (progressive cognitive decline)
Core Features (2 :probable DLB, 1: possible DLB)*
Fluctuating cognition
Recurrent well-formed, detailed visual hallucinations
Spontaneous features of parkinsonism
Suggestive Features (1+core feature: may Dx probable DLB, ≥1: may Dx possible DLB)*
REM sleep disorder
Severe neuroleptic sensitivity
Low dopamine transporter uptake in basal ganglia on SPECT or PET
Lewy Body Dementia (treatment)
Dementia with Lewy bodies (DLB) is increasingly recognized clinically as the second most common type of degenerative dementia after Alzheimer disease (AD). In addition to dementia, distinctive clinical features include: visual hallucinations, parkinsonism, cognitive fluctuations, dysautonomia, sleep disorders, and neuroleptic sensitivity. s with all of the degenerative dementias, cognitive decline in Dementia with Lewy bodies (DLB) progresses inexorably to death. Psychotic symptoms, particularly visual hallucinations, tend to persist in patients with DLB [1]. Parkinsonism also worsens over time, especially in patients for whom this is an early feature [2]. In one retrospective series, individuals with impairment of visuospatial skill on baseline neuropsychological testing had a faster rate of clinical decline compared with those who did not [3].
While some have reported that the rates of cognitive decline are similar for Alzheimer disease (AD) and DLB [4-7], others report a more stable course for DLB [8], and others have found a faster rate of cognitive decline in DLB
Treatment of Dementia with Lewy bodies (DLB) is symptomatic, targeted toward specific disease manifestations, and based upon somewhat limited evidence. There are no treatments with evidence of disease-modifying effects.
General strategies — Because medications may be poorly tolerated in DLB, nonpharmacologic, behavioral strategies aimed at modifying stressors in the environment should be employed whenever possible. (See “Treatment of behavioral symptoms related to dementia”, section on ‘Nonpharmacologic management’.) Physical therapy and mobility aids may help in the management of parkinsonism.(See “Nonpharmacologic management of Parkinson disease”.)
Patient and caregiver education regarding risks, benefits, and limitations of treatments is important. In many cases, treatment choices represent a trade-off between parkinsonism and psychosis, and the relative preferences of the patient and caregiver will be decisive.
Cognition and neuropsychiatric disturbances
Cholinesterase inhibitors — Cholinesterase inhibitors may represent a first line pharmacologic treatment in DLB. While cholinesterase inhibitors were initially developed for Alzheimer disease (AD), the evidence suggests that cholinergic deficits are even greater in DLB. Multiple anecdotal reports [13,14], open-label studies [15-17], and one randomized, controlled trial [18] suggest that cholinesterase inhibitors are efficacious in DLB, with reported benefit not only in cognition, but also for fluctuations, psychotic symptoms, and parkinsonian symptoms. In some instances, the response has been dramatic, but temporary. The effect size has been reported to be larger than that in patients with AD.
Memantine — Memantine has reported efficacy in moderate to severe Alzheimer disease and vascular dementia. A randomized controlled trial of 72 patients with either DLB or Parkinson disease dementia found that patients treated with memantine for 24 weeks performed better on the primary outcome assessment measure, the clinical global impression of change, but not on most of the other secondary outcome measures [23]. In a subsequent 24-week trial that compared memantine to placebo in 199 patients with either DLB or Parkinson disease dementia, the subset of 75 patients with DLB (but not PDD or the group overall) demonstrated improved outcome on the same primary outcome measure, but again not on most secondary outcome measures [24]. In both of these studies, memantine was well-tolerated. However, some other studies have noted that worsening of delusions and hallucinations with memantine may be particularly problematic in patients with DLB [25,26].
REM sleep disorder — REM sleep disorder often responds to low doses of clonazepam (0.25 to 1.5 mg) or melatonin (3 to 12 mg) given at bedtime [27-29]. Melatonin may be preferred in the setting of cognitive impairment. Quetiapine (12.5 mg) may also be successful, but is probably a third choice in this population.
Neuroleptics — The potential for severe neuroleptic sensitivity reactions, including exacerbation of parkinsonism, confusion, or autonomic dysfunction, limits the usefulness of neuroleptic medications in DLB.
ther psychotropic medications — There have been no systematic studies of the use of antidepressants, anxiolytics, benzodiazepines, or anticonvulsants in the treatment of the behavioral and psychiatric symptoms in DLB [4]. Selective serotonin reuptake inhibitors are commonly used in the treatment of depression. Benzodiazepines are generally AVOIDED (except for REM sleep disorder), especially for long term use, because of the potential for worsening confusion, gait disorder, and paradoxical agitation. Tricyclic agents are AVOIDED because of their anticholinergic properties. Electroconvulsive therapy has been successfully employed in depressed patients with DLB [35]. (See “Treatment of behavioral symptoms related to dementia”.)
Antiparkinson medications — Treatment of parkinsonian symptoms in DLB is similar to that for Parkinson disease (PD), if somewhat less successful [36-38]. (See“Pharmacologic treatment of Parkinson disease”, section on ‘Symptomatic therapy’.)
There is concern that these medications may exacerbate psychotic symptoms in DLB, but our clinical experience and small case series suggest that by using a conservative approach - small doses and slow upward titration - these agents are generally effective and well tolerated [21,39]. Worsening of psychotic symptoms and REM sleep disorder may require addition of a small dose of an atypical neuroleptic [39,40].
Levodopa seems to be more effective than dopamine agonists and produces fewer side effects [41]. A suggested initial dose is one-half tablet of carbidopa-levodopa (Sinemet) 25/100 mg three times daily, titrated upward over several weeks as tolerated and according to the clinical response. Anticholinergic agents are generally avoided in DLB because they may worsen cognitive function.
Orthostatic hypotension — Medical therapy can improve symptoms of orthostatic hypotension in most DLB patients [42,43]. We have used fludrocortisone, midodrine, and a combination of the two successfully in several of our patients. Anticholinergic agents for the treatment of urinary incontinence should probably be avoided in DLB patients who have orthostatic hypotension.
Ischemic Cerebrovascular Disease
Ddx?
Anatomic
- Non thrombotic:
- Watershed: hypotension/shock - bilateral weakness
- Vasospasm: cocaine, migraine - focal neuro signs
- Vasculopathy: FMD, dissxn, vaculitis - various
- Arterial:
- Embolic: cardiac (AF, DCM, IE), coaulopathy (APLS, SCD)
- Atherosclerosis/thrombosis: large vs small/lacunar
- Venous:
- Sagittal sinus thrombosis
Cold Caloric Testing
In cases of cervical fractures or indeterminate OCR testing, the VOR should be tested with cold calorics. After visual inspection to make sure that the tympanic membrane is intact, 10 cc of ice water is infused into the external auditory canal, and the eye movements are observed over the next 30 to 60 seconds. In a conscious person, the eyes will slowly move conjugately toward the side of the ice water infusion (due to ipsilateral inhibition of the vestibular complex), followed by a fast, compensatory phase away from the irrigated ear (driven by the contralateral frontal eye field). In the setting of coma due to bihemispheric disease, the fast “corrective phase” is absent (due to frontal lobe dysfunction), and the eyes remain deviated toward the side of the cold water infusion. In the setting of brainstem injury, there are no eye movements.
Midbrain CVA
WEBERS SYNDROME:
Midbrain CVA involving the 3rd nerve nucleus and cerebral peduncle – causes ophthalomoplegia & ptosis on ipsilateral side & paralysis of contralateral limb.
It is caused as a result of occlusion of the paramedian branches of the posterior cerebral artery or of basilar bifurcation perforating arteries.
Horner’s?

Pontine Bleed
Cranial nerves VI and VII are most commonly affected but III, IV, IX and X may also be involved.
Pin point pupil!
Depends on Size, location of bleed..
- A large central hemorrhage: progressive decrease in the level of consciousness rapidly leading to coma. Bilateral bulbar muscle weakness, “pinpoint” pupils, hyperthermia, and hyperventilation (or abn breathing pattern – 70%) are common associated findings. (seen most often in patients with uncontrolled hypertension).
- Contralateral hyperhidrosis in the subacute or late phase after pontine hemorrhage may be seen (thought to be secondary to disruption of contralateral inhibitory sweating pathway).
- Up to one third of patients may develop a severe headache before the onset of focal signs Vomiting may be seen in 20% of patients, and seizures (mostly flexor spasms and not true convulsions) have been reported in 30% of patients.
- Ophthalmological examination may show small pupils, absence of horizontal eye movements, and ocular bobbing.
- With large hemorrhages, bulbar musculature is invariably affected. This may increase the risk of aspiration. Silent aspiration may be difficult to recognize in the comatose patient.
- Massive pontine hemorrhage is invariably fatal; 80% of patients die within 48 hours (Silverstein 1982). Most hemorrhages occurred in the midpons at the junction of basis pontis and tegmentum. Hemorrhages frequently spread to the midbrain but rarely into the medulla. They frequently rupture into the fourth ventricle.
- Smaller hemorrhages in the tegmentum or basal regions may present with focal signs and no alteration in consciousness. Usually unsuspected until after the CT or MR scans.
- Hemorrhages restricted to the basal region present with hemiplegic deficits or ataxia-hemiparesis. Clinically, such syndromes are indistinguishable from lacunar infarction in the same region.
- With hemorrhages restricted to the lateral tegmentum, sensory deficits, ataxia, and oculomotor abnormalities (one-and-one-half syndrome, internuclear ophthalmoplegia, horizontal gaze palsies and ocular bobbing) are common findings(Payne et al 1978; Caplan and Goodvin 1982).
- Isolated symptoms such as sixth nerve palsy, sometimes bilateral (Kellen et al 1988), hemisensory or isolated facial sensory(Toratani et al 2008) disturbances, or trigeminal neuropathy (Berlit 1989) have been reported with small hemorrhages. Dystonia may be associated with pontomesencephalic lesions (Loher and Krauss 2009). Recently, phantom arm and leg phenomena have been noted after pontine hemorrhage (Tanaka et al 2008). Early recovery is seen in most patients, and complete resolution of deficits is common. In a study of 80 patients with primary pontine hemorrhage, the initial level of consciousness and the transaxial size of hematoma on CT were strongly related to the outcome (Murata et al 1999).
Complex Regional Pain Syndrome
Defn:
Sx: - I) is characterized by severe pain or burning sensation, most commonly in the hand or foot, with associated swelling, trophic skin changes, and signs or symptoms of vasomotor instability. When the hand is affected, there may be associated pain or limitation of the ipsilateral shoulder (shoulder-hand syndrome).
Findings:
Mgmt:
Note:
Multiple Sclerosis
Defn: Sx: Findings: Mgmt: Note:
Oligoclonal Banding
Defn: Note:
L’hermittes Sign
Defn: Note:
Parkinsonism (and meds)
Defn: Note: - domperidone is safe as it does not cross BBB
Dyskinesia (and meds)
Defn: Note:
Dystonia (and meds)
Defn: Note:





